Our AI Finds Ways to Slow/Reverse Atherosclerosis
WuXi NextCODE AI used to identify and validate major new therapeutic approach to slow and even reverse atherosclerosis.
Researchers at U.S.-based WuXi NextCODE and the Yale School of Medicine published two new studies in the Journal of Experimental Medicine and Nature Metabolism on novel, artificial intelligence (A.I.) approaches that breathe new life into big data for complex diseases.
The mechanism of maintaining vascular endothelial identity and integrity is largely unknown. In the issue of JEM, Richard et al. discover essential roles of ERK1/2 in maintaining endothelial homeostasis and its deletion-related serious defects in multiple tissues and organs.
Cells contributing to atherosclerotic disease are highly plastic and can shift their phenotype in a changing microenvironment. A study in Nature Metabolism now reveals that transforming growth factor-β (TGF-β) can transform endothelial cells into pro-inflammatory cells and that inhibition of TGF-β-receptor signalling in the endothelium can reverse atherosclerosis in mice.
In this webinar experts from across the pharma field discuss potential new targets and approaches for NASH therapy, and where the field will go in the near future.
WuXi NextCODE has grown over four years into a global genomic data and insights company that powers drug and diagnostic development with biopharma and medical center partners.
Study experimentally validates pioneering artificial intelligence strategy for the life sciences, accurately projecting complex disease processes using modest sets of gene expression data
With the announced $400 million investment from global investors including the Irish sovereign fund, WuXi NextCODE announced that GMI would whole genome sequence and collect detailed medical data on 400,000 Irish volunteers covering 60 major diseases, partnering with life sciences companies to analyse the data for insights.
Startup aims to identify disease modifying genes in people with milder than expected phenotypes as starting points for drug discovery programs.
Forbes discusses the impact of AI on drug development as our executive leader, Thomas Chittenden, is featured in Deep Knowledge Analytics' "Top-100 AI Leaders in Drug Discovery and Advanced Healthcare."
Although there are about 150 AI companies in the Drug Discovery space, very few of them are capable of building end-to-end solutions. Companies such as WuXi NextCODE, BenevolentAI, DeepMind Health, and Insilico Medicine are leaders in this area.
With the recent acquisition of Genomics Medicine Ireland (GMI, in Dublin), WuXi NextCODE is realizing the vision of turning advancements in genomics into improvements in drug discovery and ultimately population health, providing benefit to patients around the world.